Theravance Bio Ord (TBPH)

Jun 2, 2025, 6:00 AM EDT - 2 days ago

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

GSK

May 13, 2025, 6:00 AM EDT - 22 days ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

May 10, 2025, 4:35 PM EDT - 25 days ago

Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:00 PM EDT - 26 days ago

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025, 4:05 PM EDT - 27 days ago

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 6:00 AM EDT - 5 weeks ago

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Apr 24, 2025, 6:00 AM EDT - 5 weeks ago

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 7, 2025, 3:55 PM EDT - 2 months ago

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Mar 27, 2025, 6:00 AM EDT - 2 months ago

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Feb 26, 2025, 8:58 PM EST - 3 months ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 3 months ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 6:00 AM EST - 4 months ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Dec 17, 2024, 6:00 AM EST - 6 months ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Nov 12, 2024, 10:46 PM EST - 7 months ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 7 months ago

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Oct 24, 2024, 6:00 AM EDT - 7 months ago

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 18, 2024, 9:00 AM EDT - 8 months ago

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Aug 5, 2024, 7:37 PM EDT - 10 months ago

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 10 months ago

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 6:00 AM EDT - 11 months ago

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

May 13, 2024, 6:58 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Feb 26, 2024, 9:52 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 14, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Jan 5, 2024, 6:15 AM EST - 1 year ago

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

Jan 5, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Dec 21, 2023, 5:00 PM EST - 1 year ago

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Dec 18, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Nov 16, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Nov 15, 2023, 6:00 AM EST - 1 year ago

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

VTRS

Nov 7, 2023, 11:23 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:28 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 19, 2023, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

Sep 9, 2023, 11:49 AM EDT - 1 year ago

Theravance: Positive Findings Boost Ampreloxetine Development

Sep 8, 2023, 10:12 AM EDT - 1 year ago

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

Aug 28, 2023, 6:06 AM EDT - 1 year ago

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

Aug 7, 2023, 9:33 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

May 9, 2023, 6:00 PM EDT - 2 years ago

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

May 8, 2023, 10:39 PM EDT - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q1 2023 Earnings Call Transcript

May 8, 2023, 4:05 PM EDT - 2 years ago

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023, 4:45 AM EDT - 2 years ago

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

Apr 24, 2023, 6:00 AM EDT - 2 years ago

Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors